Editorial: Peginterferon for chronic hepatitis B: Predicting success with on-treatment benchmarks

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 9, 2010, Pages 1474-1475

  Moucari, Rami ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CIRCULAR DNA; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; PEGINTERFERON; VIRUS DNA; ALPHA2B INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2B;

EDITORIAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOMODULATION; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REMISSION; TREATMENT RESPONSE; ANALYTICAL EQUIPMENT; BLOOD; DISEASE FREE SURVIVAL; GENETICS; GENOTYPE; IMMUNOLOGY; NOTE; PREDICTIVE VALUE; QUALITY CONTROL; TIME; TREATMENT OUTCOME; VIRUS LOAD;

ANTIVIRAL AGENTS; BENCHMARKING; BIOLOGICAL MARKERS; DISEASE-FREE SURVIVAL; GENOTYPE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2B; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; REAGENT KITS, DIAGNOSTIC; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77956043221     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06372.x     Document Type: Editorial

References (15)

1. Perrillo RP. Therapy of hepatitis B - viral suppression or eradication? Hepatology 2006 43 (Suppl. 1 S182 93.
2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J. Hepatol. 2009 50 : 227 242.
3. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007 45 : 507 539.
4. Lampertico P, Del Ninno E, Viganò M et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003 37 : 756 763.
5. Moucari R, Korevaar A, Lada O et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J. Hepatol. 2009 50 : 1084 1092.
6. Buster EH, Flink HJ, Cakaloglu Y et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008 135 : 459 467.
7. Marcellin P, Bonino F, Lau GK et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009 137 : 2002 2009.
8. Marcellin P, Heathcote EJ, Buti M et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med. 2008 359 : 2442 2455.
9. Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology 2009 49 (Suppl. 5 S103 11.
10. Bonino F, Marcellin P, Lau GK et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007 56 : 699 705.
11. Buster EH, Hansen BE, Lau GK et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009 137 : 2002 2009.
12. Perrillo RP. Hepatitis B surface antigen quantification as a current-day paradox: obtaining the gold in the face of diminishing return. Hepatology 2009 49 : 1063 1065.
13. Moucari R, Mackiewicz V, Lada O et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009 49 : 1151 1157.
14. Ma H, Yang RF, Wei L. Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients. J. Gastroenterol. Hepatol. 2010 25 : 1498 1506.
15. Fried MW, Piratvisuth T, Lau GK et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008 47 : 428 434.